Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Myelodysplastic Syndromes 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1Advanced Lung Neuroendocrine Tumor 1

Interventions

Temozolomide 31Radiotherapy 25Magnetic Resonance Spectroscopy 17Radiation 13Surgical Procedures, Operative 12Specimen Handling 9Radiotherapy, Conformal 9Bevacizumab 9Immunoglobulin G 8Disulfides 8Carmustine 8Vorinostat 7Radiotherapy, Intensity-Modulated 7Erlotinib Hydrochloride 7Chemotherapy, Adjuvant 7temsirolimus 6cediranib 6Sirolimus 6motexafin gadolinium 5Sorafenib 5Nivolumab 5Cilengitide 5Carboplatin 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5tipifarnib 4Lapatinib 4Congresses as Topic 4veliparib 3Procarbazine 3O(6)-benzylguanine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Glioblastoma × Photons × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡